-
公开(公告)号：US20090192191A1
公开(公告)日：2009-07-30
申请号：US10585420
申请日：2005-01-07
IPC分类号： A61K31/4709 , C07D401/12 , C07D207/38 , C07D405/14 , C07D409/14 , A61K31/4015 , A61P19/02
CPC分类号： C07D409/14 , C07D401/12 , C07D405/14
摘要： The present invention relates to novel compounds of formula (I) and their pharmaceutically useful compositions as MMP and TNF inhibitors.
摘要翻译： 本发明涉及新的式（I）化合物及其药学上有用的组合物作为MMP和TNF抑制剂。
-
公开(公告)号：US20090171091A1
公开(公告)日：2009-07-02
申请号：US12374089
申请日：2007-07-27
IPC分类号： C07D215/48
CPC分类号： C07C237/30 , C07C2601/14 , C07D215/48 , C07D405/12
摘要： Disclosed herein in the embodiments of the present invention are the compounds suitable as modulators of HDL having general formula (1), novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to a process of preparing compounds of general formula (1), their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.
摘要翻译： 在本发明的实施方案中公开的是适合作为具有通式（1）的HDL的调节剂的化合物，涉及其合成的新中间体，其药学上可接受的盐和含有它们的药物组合物。 本发明还涉及制备通式（1）的化合物，其互变异构形式，其药学上可接受的盐，含有它们的药物组合物和参与其合成的新中间体的方法。
-
公开(公告)号：US20120220590A1
公开(公告)日：2012-08-30
申请号：US13387844
申请日：2010-07-30
IPC分类号： A61K31/5377 , A61K31/34 , C07D333/20 , A61K31/381 , C07D213/57 , A61K31/44 , C07D401/12 , A61K31/4439 , C07D309/10 , A61K31/351 , C07D277/28 , A61K31/426 , C07D413/12 , A61K31/444 , A61P29/00 , A61P37/00 , A61P37/08 , C07D307/06
CPC分类号： C07C323/12 , C07C311/08 , C07D213/30 , C07D213/40 , C07D213/65 , C07D231/12 , C07D261/08 , C07D263/14 , C07D277/24 , C07D305/06 , C07D307/12 , C07D307/42 , C07D307/58 , C07D309/12 , C07D333/16 , C07D407/12
摘要： Compounds of formula (I) and pharmaceutical compositions containing them are described. The use of the compounds and compositions are also described.
摘要翻译： 描述式（I）化合物和含有它们的药物组合物。 还描述了化合物和组合物的用途。
-
公开(公告)号：US20100280024A1
公开(公告)日：2010-11-04
申请号：US12682720
申请日：2008-10-13
IPC分类号： A61K31/536 , C07D215/14 , A61K31/47 , C07D217/00 , C07D265/36 , C07D211/32 , A61K31/445 , C07D403/02 , A61K31/506 , C07D241/04 , A61K31/495 , C07D207/00 , A61K31/40 , C07D295/00 , A61K31/5375 , A61K31/4709 , C07D401/00 , A61K31/4545 , A61P9/12
CPC分类号： C07D215/08 , C07D207/14 , C07D207/16 , C07D209/08 , C07D211/16 , C07D211/22 , C07D213/64 , C07D215/12 , C07D215/14 , C07D215/18 , C07D215/20 , C07D215/26 , C07D217/06 , C07D265/36 , C07D295/185 , C07D401/06 , C07D403/04
摘要： The present invention relates to renin inhibitors of formula (I), their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to a process of preparing compounds of general formula (I), their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.
摘要翻译： 本发明涉及式（I）的肾素抑制剂，其药学上可接受的盐和含有它们的药物组合物。 本发明还涉及制备通式（I）的化合物，其互变异构形式，其药学上可接受的盐，含有它们的药物组合物和涉及其合成的新中间体的方法。
-
公开(公告)号：US08022217B2
公开(公告)日：2011-09-20
申请号：US12374089
申请日：2007-07-27
IPC分类号： C07D215/38
CPC分类号： C07C237/30 , C07C2601/14 , C07D215/48 , C07D405/12
摘要： Disclosed herein in the embodiments of the present invention are the compounds suitable as modulators of HDL having general formula (1), novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to a process of preparing compounds of general formula (1), their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.
摘要翻译： 在本发明的实施方案中公开的是适合作为具有通式（1）的HDL的调节剂的化合物，涉及其合成的新中间体，其药学上可接受的盐和含有它们的药物组合物。 本发明还涉及制备通式（1）的化合物，其互变异构形式，其药学上可接受的盐，含有它们的药物组合物和参与其合成的新中间体的方法。
-
-
-
-
搜索结果
5 条记录 (耗时 0.038 秒)
